Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7389 in Hormone Refractory Prostate Cancer
NCT00278993Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2006
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in prostate cancer (PCa), sponsored by Eisai Co., Ltd.. Started Jan 2006; status: completed.
02
Drugs
eribulin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00278993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00278993.